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Abstract
BACKGROUND—High-dose erythropoietin has been shown to have a neuroprotective effect in
preclinical models of neonatal brain injury, and phase 2 trials have suggested possible efficacy;
however, the benefits and safety of this therapy in extremely preterm infants have not been
established.
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METHODS—In this multicenter, randomized, double-blind trial of high-dose erythropoietin, we
assigned 941 infants who were born at 24 weeks 0 days to 27 weeks 6 days of gestation to receive
erythropoietin or placebo within 24 hours after birth. Erythropoietin was administered
intravenously at a dose of 1000 U per kilogram of body weight every 48 hours for a total of six

Address reprint requests to Dr. Juul at the Department of Pediatrics, Division of Neonatology, University of Washington, Box 356320,
Seattle, WA 98195, or at sjuul@uw.edu.
*A list of investigators in the PENUT Trial Consortium is provided in the Supplementary Appendix, available at NEJM.org.
A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.
Dr. Hartman reports receiving consulting fees from Best Doctors. No other potential conflict of interest relevant to this article was
reported.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Juul et al.

Page 2

Author Manuscript

doses, followed by a maintenance dose of 400 U per kilogram three times per week by
subcutaneous injection through 32 completed weeks of postmenstrual age. Placebo was
administered as intravenous saline followed by sham injections. The primary outcome was death
or severe neurodevelopmental impairment at 22 to 26 months of postmenstrual age. Severe
neurodevelopmental impairment was defined as severe cerebral palsy or a composite motor or
composite cognitive score of less than 70 (which corresponds to 2 SD below the mean, with higher
scores indicating better performance) on the Bayley Scales of Infant and Toddler Development,
third edition.

Author Manuscript

RESULTS—A total of 741 infants were included in the per-protocol efficacy analysis: 376
received erythropoietin and 365 received placebo. There was no significant difference between the
erythropoietin group and the placebo group in the incidence of death or severe
neurodevelopmental impairment at 2 years of age (97 children [26%] vs. 94 children [26%];
relative risk, 1.03; 95% confidence interval, 0.81 to 1.32; P = 0.80). There were no significant
differences between the groups in the rates of retinopathy of prematurity, intracranial hemorrhage,
sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, or death or in the frequency of
serious adverse events.
CONCLUSIONS—High-dose erythropoietin treatment administered to extremely preterm infants
from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of
severe neurodevelopmental impairment or death at 2 years of age. (Funded by the National
Institute of Neurological Disorders and Stroke; PENUT ClinicalTrials.gov number,
NCT01378273.)

Author Manuscript

Advances in the care of infants born before 28 weeks of gestation have been associated with
a dramatic improvement in survival.1 However, one or more major impairments (e.g.,
cerebral palsy, intellectual disability, deafness, or blindness) develop in approximately 40%
of infants born before 28 weeks.2,3 In addition, long-term follow-up studies have
increasingly identified a higher risk of behavioral disorders — including attention-deficit
disorder,4 autism,5 and psychiatric disorders6 — among children born preterm than among
those born at term. There is a critical need for neuroprotective agents that can improve
outcomes in preterm infants.7,8

Author Manuscript

Erythropoietin, which is used clinically for its erythropoietic effects, is also an important
trophic factor in fetal brain development.9–12 Erythropoietin has been shown to have
neuroprotective effects in preclinical models of neonatal brain injury.13 In addition, results
of a meta-analysis of four randomized, controlled trials involving a total of 1133 infants
showed that fewer infants who received erythropoietin than those who received placebo had
a score of less than 70 (which corresponds to 2 SD below the mean, with higher scores
indicating better performance) on the Mental Developmental Index of the Bayley Scales of
Infant and Toddler Development, third edition (Bayley-III) (odds ratio, 0.51; 95%
confidence interval [CI], 0.31 to 0.81; number needed to treat to prevent a score of <70 in
one child, 14).14 We performed the Preterm Erythropoietin Neuroprotection Trial (PENUT),
a phase 3, randomized, placebo-controlled, double-blind trial, to assess the safety and
efficacy of early high-dose erythropoietin for neuroprotection in extremely preterm infants.
15
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METHODS
PATIENTS, TRIAL DESIGN, AND OVERSIGHT
Infants were eligible if they were born between 24 weeks 0 days and 27 weeks 6 days of
gestation. Parental consent was obtained before or after birth, as permitted by the
institutional review board at each site. Exclusion criteria were known life-threatening
anomalies, chromosomal anomalies, disseminated intravascular coagulopathy, twin-to-twin
transfusion, a hematocrit level above 65%, hydrops fetalis, or known congenital infection.
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Randomization was stratified according to recruitment site, single or multiple birth, and
gestational age (24 weeks 0 days to 25 weeks 6 days or 26 weeks 0 days to 27 weeks 6
days). We used block randomization within sites with variable blocks of 4, 6, 8, and 10
infants. Infants from the same pregnancy (i.e., twins or triplets) were assigned to the same
group. Randomization sequences were generated at a central data coordinating center and
were provided directly to the research pharmacy with the use of a trial binder that contained
the complete set of trial identification numbers and associated randomization assignments.
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Enrollment and initial administration of erythropoietin or placebo occurred within 24 hours
after birth. Infants received erythropoietin at a dose of 1000 U per kilogram or placebo
(saline) intravenously every 48 hours for a total of six doses; thereafter, infants received
maintenance subcutaneous injections of erythropoietin at a dose of 400 U per kilogram of
body weight or sham injections, three times per week through 32 weeks 6 days of
postmenstrual age. With the exception of the staff at the data coordinating center, the site
pharmacist, and the staff who administered the maintenance injections, all trial personnel
were unaware of the trial-group assignments. Additional details of the protocol have been
published previously15; the protocol, with the statistical analysis plan, is available with the
full text of this article at NEJM.org.
The trial was approved by the institutional review board at each participating site and was
registered with the Food and Drug Administration (investigational new drug application
12656).15 The first, second, and last authors vouch for the accuracy and completeness of the
data and analyses and for the fidelity of the trial to the protocol.
ULTRASONOGRAPHY, IRON SUPPLEMENTATION, AND TRANSFUSIONS
After enrollment and before the administration of erythropoietin or placebo, ultrasonography
of the head was performed. Sequential ultrasonographic images were obtained as part of
routine clinical care on day 7, 8, or 9 and at 36 weeks of postmenstrual age.

Author Manuscript

If breast milk was unavailable, infants received a standard iron-containing formula. All
infants began receiving iron supplementation when their enteral feeding volume had reached
60 ml per kilogram per day and they were at least 7 days old. Infants initially received 3 mg
per kilogram per day of enteral iron. The dose was increased to 6 mg per kilogram per day
when infants reached a feeding volume of 100 to 120 ml per kilogram per day.16 Serum
ferritin or the ratio of zinc protoporphyrin to heme17 was assessed on days 14 and 42, and
the dose of supplemental iron was adjusted accordingly. Infants who did not receive enteral
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feedings received parenteral iron (1.5 mg per kilogram twice a week, adjusted on the basis
of the ratio of zinc protoporphyrin to heme or serum ferritin values).
Site-specific transfusion practices were allowed. The transfusion strategies used by the trial
sites ranged from liberal to restrictive, which reflects the current lack of consensus regarding
guidelines for transfusion strategies.18
PRIMARY OUTCOME
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The primary outcome was death or severe neurodevelopmental impairment at 22 to 26
months of postmenstrual age. Severe neurodevelopmental impairment was defined as the
presence of severe cerebral palsy or a Bayley-III composite motor score or composite
cognitive score of less than 70. Cerebral palsy was classified as hemiplegia, diplegia, or
quadriplegia, and severity was determined according to the Gross Motor Function
Classification System (GMFCS) (levels range from 0 [no impairment] to 5 [most severe
impairment]). Severe cerebral palsy was defined as a GMFCS level higher than 2.19–22
Personnel who performed the Bayley-III assessments and standardized neurologic
examinations were certified centrally. To minimize bias, the examiners were unaware of the
participants’ medical histories and the results of brain-imaging studies.
SECONDARY OUTCOMES

Author Manuscript

The key secondary outcome was death or moderate-to-severe neurodevelopmental
impairment. Moderate-to-severe neurodevelopmental impairment was defined as moderate
cerebral palsy (a GMFCS level of 2) or a Bayley-III composite motor score or composite
cognitive score of less than 85 (which corresponds to 1 SD below the mean).15 Other
prespecified secondary outcomes were adverse events and death or severe
neurodevelopmental impairment assessed according to sex. A subgroup of 220 infants at
selected sites underwent magnetic resonance imaging of the head at 36 weeks of
postmenstrual age, and plasma biomarkers were evaluated. Additional secondary analyses
involving these measures are described in the statistical analysis plan and are not reported
here. Data regarding transfusions (average cumulative volume, number of transfusions, and
the number of unique donors per infant) were compared between groups in post hoc
analyses.
ADVERSE EVENTS

Author Manuscript

We recorded the incidence and severity of common sequelae of prematurity:
bronchopulmonary dysplasia (defined by the use of supplemental oxygen at 36 weeks of
postmenstrual age),23 any intracranial hemorrhage (classified according to Papile grade),24
periventricular leukomalacia,25 any culture-positive sepsis, any stage of necrotizing
enterocolitis (classified according to Bell’s stage, with stages ranging from 1 to 3 and higher
stages indicating greater severity of disease),26 patent ductus arteriosus, any stage of
retinopathy of prematurity,27 and hemangiomas present on day 5 or at the time of the
physical examination performed at discharge.
Serious adverse events were prespecified and had to be reported within 72 hours after
identification. Serious adverse events that were classified as potentially related to
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erythropoietin on the basis of safety profiles in adults included any symptomatic thrombosis
involving a major vessel that was unrelated to an infusion catheter and that resulted in
anticoagulation therapy (e.g., superior vena cava syndrome), polycythemia (defined as a
hematocrit level >65% [measured from a blood sample obtained from a vein] or an increase
of ≥15% in hematocrit level in the absence of a preceding blood transfusion), hypertension
(defined by receipt of antihypertensive therapy for more than 1 month, discharge with
medication, or both), or other expected or unexpected life-threatening event. Serious adverse
events potentially related to prematurity (but not necessarily to erythropoietin) included
severe pulmonary hemorrhage, severe necrotizing enterocolitis (defined as Bell’s stage 2b or
3),26 severe retinopathy of prematurity resulting in laser surgery or bevacizumab therapy,
severe sepsis (defined as culture-proven bacterial or fungal sepsis resulting in blood-pressure
support or substantive new respiratory support), grade 3 or 4 intracranial hemorrhage,
cardiac arrest that did not result in death, and death.

Author Manuscript

STATISTICAL ANALYSIS
Our trial design assumed that 18% of the infants would die and that trial-group assignment
would have no effect on mortality; moreover, we hypothesized that treatment with
erythropoietin would result in a 25% lower rate of neurodevelopmental impairment than
placebo (30% vs. 40%). We calculated that 376 infants per group (a total of 752) would be
needed to give the trial more than 80% power to show this 25% difference.15 Because
multiple births account for 25% of extremely preterm infants, we increased the total sample
size to 846 infants, using a variance inflation factor of 1.125 to account for correlation
within siblings from the same pregnancy (assuming a correlation of 0.5 and an average
cluster size of 1.25). We anticipated attrition of 12.5% of the infants and therefore planned
for an overall total enrollment of 940 infants.

Author Manuscript
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A modified intention-to-treat approach was used for the safety analysis, which included all
infants who underwent randomization and received the first dose of erythropoietin or
placebo. The safety analysis compared the percentage of serious adverse events in the two
groups that occurred from the time of the first dose to the time of hospital discharge. For
comparisons between groups, we accounted for potential correlation within siblings from
multiple gestations by using generalized estimating equations with robust standard errors to
provide valid statistical inference and to fully account for the potential correlation of
outcomes in siblings from the same pregnancy. We used a Wald test with a Poisson
regression model for the analysis of total serious adverse events and a logistic-regression
model for the analysis of individual events, with adjustment for gestational age at birth (24
weeks 0 days to 25 weeks 6 days or 26 weeks 0 days to 27 weeks 6 days) and recruitment
site as fixed effects. All other noncategorical data were assessed with generalized estimating
equation regression models appropriate for continuous outcomes.
We also evaluated the primary outcome of death or neurodevelopmental impairment using
generalized estimating equations to account for potential correlation within siblings from the
same pregnancy, with adjustment for gestational age at birth and recruitment site as a fixed
effect. The primary analysis included infants with complete data and excluded data from
infants known to be alive but in whom neurodevelopmental outcomes were not assessed. In
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sensitivity analyses, we included infants who died before the first infusion, outcomes
regarding neurodevelopmental impairment in infants who were not followed up within the
follow-up window, and adjudicated consensus outcomes regarding neurodevelopmental
impairment in infants with missing data for the primary outcome because of a partially
completed follow-up examination. For the remaining infants with missing data on
neurodevelopmental impairment outcomes, we conducted multiple-imputation analyses with
the multivariate imputation by chained equations (MICE) algorithm in R software28 (10
imputations) to impute missing data on neurodevelopmental impairment using variables,
determined at baseline and through telephone follow-up, associated with missing primaryoutcome data owing to loss to follow-up or data missing because an assessment was not
possible owing to neurodevelopmental impairment in the child. Subgroups defined
according to sex and gestational age at birth were prespecified; the heterogeneity of effect
with respect to the primary outcome was evaluated separately for each subgroup variable
with the use of a Wald test for the interaction between each term and treatment. Confidence
intervals are reported for the treatment effect in each subgroup.
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A two-sided significance level of 0.05 was used for the prespecified efficacy hypothesis test
and for the final safety analysis that compared serious adverse events between groups. An
independent data and safety monitoring board formally reviewed the accumulated serious
adverse events in three interim analyses (when 25%, 50%, and 75% of infants had been
enrolled). A fourth (final) analysis used significance thresholds of 0.031 for death and 0.004
for the 10 individual serious adverse events because of sequential monitoring with an
O’Brien–Fleming stopping boundary. All other comparisons were considered exploratory
and were not adjusted for multiple testing. Statistical analyses were performed with the use
of R software, version 3.3.0.

Author Manuscript

RESULTS
PATIENTS

Author Manuscript

A total of 941 infants were enrolled from December 2013 through September 2016 at 19
sites that comprised 30 hospitals; 477 infants were assigned to the erythropoietin group and
464 to the placebo group (Fig. 1). Three infants in the placebo group and 1 infant in the
erythropoietin group died before administration of the first infusion and were not included in
the analyses. One infant in the placebo group was excluded because of a complication with
consent. The modified intention-to-treat population for the evaluation of safety therefore
included 476 infants assigned to erythropoietin and 460 assigned to placebo. The evaluation
of efficacy at 2 years of age included 376 children in the erythropoietin group (79%) and
365 in the placebo group (79%).
The baseline characteristics of the mothers, infants, and pregnancies are shown in Table 1.
The majority of infants received all six intravenous doses (432 of 476 infants [91%] in the
erythropoietin group and 424 of 460 infants [92%] in the placebo group); 25 infants (5%) in
the erythropoietin group and 26 (6%) in the placebo group died before they received all six
doses. The number of infants who received all subcutaneous doses of erythropoietin or all
placebo sham injections was similar in the two groups (389 infants [82%] in the
erythropoietin group and 390 [85%] in the placebo group). A similar number of infants in
N Engl J Med. Author manuscript; available in PMC 2020 July 16.
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the two groups (420 [88%] in the erythropoietin group and 412 [90%] in the placebo group)
were discharged alive; the time until discharge was also similar in the two groups (median,
101 days [interquartile range, 82 to 121] and 102 days [interquartile range, 86 to 128],
respectively).
OUTCOMES

Author Manuscript

Death or severe neurodevelopmental impairment occurred in 97 of 376 children (26%) in the
erythropoietin group and in 94 of 365 (26%) in the placebo group (relative risk, 1.03; 95%
CI, 0.81 to 1.32; P = 0.80) (Fig. 2). Death occurred in 13% in the erythropoietin group and
in 11% in the placebo group (relative risk, 1.27; 95% CI, 0.91 to 1.79), and severe
neurodevelopmental impairment occurred in 11% and 14%, respectively (relative risk, 0.79;
95% CI, 0.51 to 1.22). The rate of death or severe neurodevelopmental impairment was
lower among children who had been born at a later gestational age, but there was no
difference in treatment effect according to gestational-age group or sex. No meaningful
treatment effect was observed with respect to moderate neurodevelopmental impairment or
in sensitivity analyses of the primary outcome that included deaths that occurred before the
first dose (4 infants), outcome assessments that were not performed within the prespecified
time windows (53 infants), or adjudicated outcomes because of partially completed followup examinations (25 infants). An analysis that used multiple imputation for missing primaryoutcome data showed results that were similar to those of the primary analysis (117 children;
relative risk, 1.00; 95% CI, 0.80 to 1.25).
ADVERSE EVENTS

Author Manuscript

No significant differences between groups were observed in the percentage of infants with
serious adverse events or common complications of prematurity. The frequencies of severe
bronchopulmonary dysplasia, medically or surgically treated patent ductus arteriosus, and all
grades of intracranial hemorrhage, necrotizing enterocolitis, and retinopathy of prematurity
were similar in the two groups (Fig. 3). Among infants discharged home, hemangiomas
occurred in 32 of 420 (8%) in the erythropoietin group and in 26 of 412 (6%) in the placebo
group. In post hoc analyses, the median number of transfusions was 2 (interquartile range, 0
to 5) in the erythropoietin group and 4 (interquartile range, 2 to 7) in the placebo group.
(Additional post hoc analyses of transfusions and iron supplementation in the two groups are
shown in Figs. S2 and S3 in the Supplementary Appendix, available at NEJM.org.) The use
of concomitant medications was similar in the two groups (Fig. S4).

DISCUSSION
Author Manuscript

In this multicenter, placebo-controlled, randomized trial of the use of erythropoietin in
extremely preterm infants, we found no significant difference between groups in the primary
outcome of death or severe neurodevelopmental impairment at 2 years of age. These results
are in contrast to the conclusion of a meta-analysis of four randomized trials that showed
that erythropoietin reduced the risk of a Mental Developmental Index score of less than 70 at
a postmenstrual age of 18 to 22 months but showed no significant effect with respect to
motor function, hearing, or vision.14 Previous studies have used different dosing regimens
and different durations of treatment: 400 U per kilogram, starting within 48 hours after
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birth29 or within 96 hours after birth30 and administered three times a week through 35
weeks of postmenstrual age; 3000 U per kilogram, administered within 3 hours after birth, at
12 to 18 hours after birth, and at 36 to 42 hours after birth31; and 500 U per kilogram,
administered every other day for 2 weeks beginning within 72 hours after birth.32 Moreover,
the infants enrolled in these studies were, on average, more mature (27 weeks to 30 weeks of
gestational age at birth) than the infants in our trial.31,32

Author Manuscript

The current trial is larger than the previous trials, and the infants included in this trial were
born at 24 weeks 0 days to 27 weeks 6 days of gestation. On the basis of animal models of
brain injury, we chose a high initial erythropoietin dose to achieve neuroprotective serum
levels during the first days after birth, when physiologic vulnerability is highest.33,34 The
maintenance dose was chosen on the basis of previous studies of erythropoiesis-stimulating
agents, with some smaller studies showing both hematologic and neurologic benefit.29 The
duration of treatment was determined on the basis of the period of oligodendrocyte
vulnerability (24 weeks to 32 weeks of gestational age).35 We speculate that the contributing
factors to neurologic dysfunction are heterogeneous and that the targets that are responsive
to erythropoietin may be diluted by pathways not affected by erythropoietin, particularly in
the most premature infants.

Author Manuscript

A limitation of this trial was the use of neurodevelopmental testing at 2 years of age, which
provides less reliable information than assessments performed at older ages.36 In some
children who were born preterm, evaluations performed at older ages show that
neurodevelopmental outcomes are better than when the child was evaluated at a younger
age; in other children, assessments performed at older ages show that neurodevelopmental
outcomes have become worse. A meta-analysis of 24 studies showed that positive predictive
values of evaluations, performed with the use of either Bayley-III or the Griffiths Scales of
Mental Development, from 1 to 3 years of age ranged from 20 to 89%, and negative
predictive values ranged from 48 to 95% when children were assessed after 5 years of age.
The sensitivity of early assessment to identify cognitive deficit in school-age children was
55% (95% CI, 46 to 64), and the specificity was 84% (95% CI, 77 to 89).37 Long-term
follow up of the PENUT cohort is needed to identify cognitive and physical problems that
may not become apparent until later in life.
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The rate of death or severe neurodevelopmental impairment (26%) was lower than the
predicted rate of 40%; similarly, the observed rate of the composite outcome of death or
moderate-to-severe neurodevelopmental impairment (48%) was lower than the anticipated
rate of 60%. The difference between the observed and predicted rates was most likely the
result of our exclusion of infants with conditions known to be associated with a higher risk
of death and conditions known to have adverse effects on neurodevelopment.
We found no meaningful differences between groups in any serious adverse events,
including those known to occur in adults who receive long-term erythropoietin treatments
(e.g., hyper-tension, thromboses, and polycythemia), or in common complications known to
occur in extremely preterm infants. Specifically, in contrast to previous meta-analyses,
treatment with erythropoietin did not result in a higher rate or greater severity of retinopathy
of prematurity than placebo.38–40 No other safety concerns arose in this trial — a finding
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similar to that in the other published studies of erythropoietin for neuroprotection in
neonates.14 In post hoc analyses, we found that the erythropoietin dosing regimen used in
PENUT stimulated erythropoiesis, as evidenced by the lower number and lower volume of
transfusions and the lower exposure to blood donors in the erythropoietin group than in the
placebo group.
In summary, we did not observe that treatment with high-dose erythropoietin in extremely
preterm infants resulted in a lower risk of death or in better neurodevelopmental outcomes at
2 years of age than placebo.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Screening, Randomization, and Follow-up.
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Figure 2. Primary and Secondary Efficacy Outcomes.
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The primary outcome was death or severe neurodevelopmental impairment at 22 to 26
months of postmenstrual age. Severe neurodevelopmental impairment was defined as severe
cerebral palsy or a composite motor score or composite cognitive score of less than 70
(which corresponds to 2 SD below the mean, with higher scores indicating better
performance) on the Bayley Scales of Infant and Toddler Development, third edition
(Bayley-III). Severe cerebral palsy was defined as a Gross Motor Function Classification
System (GMFCS) level higher than 2 (levels range from 0 [no impairment] to 5 [most severe
impairment]). Moderate-to-severe neurodevelopmental impairment was defined as moderate
cerebral palsy (a GMFCS level of 2) or a Bayley-III composite motor score or composite
cognitive score of less than 85 (which corresponds to 1 SD below the mean). Relative risks
were generated with the use of generalized estimating equation models adjusted for
gestational age at birth and recruitment site and accounting for clustering of siblings from
the same pregnancy. The diamonds indicate that the result is a key measure of interest; the
center of the diamond represents the point estimate, and the width of the diamond represents
the 95% confidence interval.
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Figure 3. Adverse Events.
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Relative-risk estimates were generated with the use of generalized estimating equation
models adjusted for gestational age at birth and clustering of siblings from the same
pregnancy. The relative risk and 95% confidence interval were not calculated for
polycythemia because of the small number of events. The diamonds indicate that the result is
a key measure of interest; the center of the diamond represents the point estimate, and the
width of the diamond represents the 95% confidence interval. Necrotizing enterocolitis was
classified according to Bell’s stage (stages range from 1 to 3, with higher stages indicating
greater severity of disease). Intracranial hemorrhage was classified according to Papile
grade. In the category of complications of prematurity, data for severe bronchopulmonary
dysplasia are shown for the 459 infants in the erythropoietin group and the 446 infants in the
placebo group who survived to 36 weeks of post-natal age, and data for retinopathy of
prematurity are shown for the 424 infants in the erythropoietin group and the 421 infants in
the placebo group who had an ophthalmologic examination before discharge. The total
numbers of serious adverse events per patient were evaluated with the use of generalized
estimating equation models appropriate for count data. The assessment of blood transfusions
was a post hoc analysis.
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104 (22)

Hispanic ethnic group — no. (%)†

131 (28)
36 (8)

Black

Unknown or not reported

153 (32)
113 (24)
62 (13)

Some college

College degree or greater

Unknown or not reported
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113 (24)
121 (25)

25 wk

219 (46)

24 wk

Gestational age at birth — no. (%)

Female sex — no. (%)

Infant characteristics

125 (26)

337 (71)

Cesarean delivery — no. (%)

Pregnancy with multiple fetuses — no. (%)

79 (17)

Delivery complications — no. (%)¶

171/346 (49)

374 (79)

Delayed cord clamping — no./total no. (%)

430 (90)

39 (8)

Pregnancy-induced hypertension — no. (%)

Prenatal magnesium sulfate use — no. (%)

349 (73)

Risk of infection — no. (%)§

Prenatal glucocorticoid use — no. (%)

76 (16)

Maternal indications for delivery — no. (%)‡

Complications of pregnancy

Pregnancy characteristics

148 (31)

High school or less

Education — no. (%)

309 (65)

White

Race — no. (%)†

29.1±6.2

Erythropoietin (N = 476)

Age — yr

Maternal characteristics

Characteristic

Author Manuscript

Maternal, Pregnancy, and Infant Characteristics at Enrollment.*

124 (27)

119 (26)

229 (50)

118 (26)

147/334 (44)

314 (68)

70 (15)

375 (82)

412 (90)

32 (7)

340 (74)

76 (17)

50 (11)

119 (26)

132 (29)

159 (35)

49 (11)

109 (24)

302 (66)

96 (21)

28.8±6.2

Placebo (N = 460)
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20.0 (14.8–23.3)

94 (20)

85 (18)

6.2±2.1

81 (18)

78 (17)

792.9±182.2

25.8±1.1

99 (22)

118 (26)

Delivery complications were defined as the presence of one or more of the following complications during delivery: cord prolapse, true cord knot, tear or rupture of the cord, placental abruption, twin-totwin transfusion, fetal or maternal bleeding, uterine rupture, or complications related to delivery with instruments.

Risk of infection was defined as pyrexia, chorioamnionitis, prolonged rupture of membranes, administration of antibiotic agents, or preterm labor.

Maternal indications for delivery were defined as eclampsia, preeclampsia, or seizures.

§

¶

Median age at first infusion (interquartile range) — hr

Hispanic ethnic group and race were reported by the mother.

†

‡

100 (21)
21.1 (15.3–23.5)

Intracranial hemorrhage before first infusion — no. (%)

6.1±2.2

Apgar score at 5 min
104 (22)

80 (17)

Apgar score <5 at 5 min — no. (%)

69 (14)

Head circumference <10th percentile — no. (%)

806.4±194.6

Weight <10th percentile for gestational age — no. (%)

Weight — g

26.0±1.2

139 (29)

Mean gestational age at birth — wk

103 (22)

27 wk

Plus–minus values are means ±SD. Percentages may not total 100 because of rounding.

*
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26 wk

Placebo (N = 460)
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